estrogen receptor
Eli Lilly's SERD Benefits Endocrine-Resistant Breast Cancer Patients as Single-Agent, Combination
Premium
Imlunestrant by itself benefited those with ESR1 mutations but also had broad efficacy in ER-positive HER2-negative tumors when combined with a CDK4/6 inhibitor.
NICE Declines to Recommend Menarini's Orserdu in ESR1-Mutant Breast Cancer in England
In a draft guidance, the institute did not recommend Orserdu, but is collecting additional data and public comments on this preliminary decision.
Concr Exploring Biomarkers of Response to Neoadjuvant TNBC Therapy
The firm will use its AI-based platform to create "digital twins" of TNBC patients and predict neoadjuvant treatment response.
European Commission Approves AstraZeneca's Truqap With Faslodex in ER-Positive Breast Cancer
Truqap will be the first AKT inhibitor approved in Europe for patients with ER-positive breast cancers harboring PIK3CA, AKT1, and PTEN mutations.
AstraZeneca's Truqap Misses Primary Endpoint in Phase III Triple-Negative Breast Cancer Trial
A combination of Truqap and paclitaxel did not improve the overall survival of patients with advanced triple-negative breast cancer.
Jun 1, 2024
Apr 19, 2023